{"id":2595,"date":"2020-10-21T00:00:00","date_gmt":"2021-03-18T01:15:51","guid":{"rendered":"https:\/\/www.eisai.com.cn\/?p=2595"},"modified":"2021-03-18T09:15:51","modified_gmt":"2021-03-18T01:15:51","slug":"notice-regarding-biogens-disclosure-about-the-submission-of-marketing-authorization-application-to-european-medicines-agency-for-aducanumab-for-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.eisai.com.cn\/en\/2020\/10\/21\/notice-regarding-biogens-disclosure-about-the-submission-of-marketing-authorization-application-to-european-medicines-agency-for-aducanumab-for-alzheimers-disease\/","title":{"rendered":"NOTICE REGARDING BIOGEN\u2019S DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR ADUCANUMAB FOR ALZHEIMER\u2019S DISEASE"},"content":{"rendered":"<p>Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \u201cEisai\u201d) announced today that Biogen (Nasdaq: BIIB) has disclosed its submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the review of aducanumab, an investigational treatment for Alzheimer\u2019s disease, as of October 2020 in its Q3 2020 Earnings Press Release issued on October 21. This MAA is subject to validation of whether the EMA accepts the application for review, which Biogen plans to announce when notified.<\/p>\n<p>&nbsp;<\/p>\n<p><strong><span class=\"txt-b\">Media Inquiries:<\/span><\/strong><br \/>\nPublic Relations Department,<br \/>\nEisai Co., Ltd.<br \/>\n+81-(0)3-3817-5120<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \u201cEisai\u201d) announced today that Biogen (Nasdaq: BIIB) has disclosed its submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the review of aducanumab, an investigational treatment for Alzheimer\u2019s disease, as of October 2020 in its Q3 2020 Earnings Press Release issued on October 21. This MAA is subject to validation of whether the EMA accepts the application for review, which Biogen plans to announce when notified.<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[28],"tags":[],"class_list":["post-2595","post","type-post","status-publish","format-standard","hentry","category-news-en"],"_links":{"self":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/2595"}],"collection":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/comments?post=2595"}],"version-history":[{"count":2,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/2595\/revisions"}],"predecessor-version":[{"id":2598,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/2595\/revisions\/2598"}],"wp:attachment":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/media?parent=2595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/categories?post=2595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/tags?post=2595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}